For many patients, dental procedures can cause a great deal of anxiety and fear. These emotions are part of a stress reaction, which, in physiologic terms, can pose a serious risk, particularly to patients with pre-existing cardiopulmonary disorders. In each case the dentist must decide whether anxiolytic stress-reducing treatment is indicated, and which method should be used. Besides certain psychotherapeutic techniques, numerous drugs (neuroleptics, barbiturates, beta-blockers, and benzodiazepines) are available for this purpose. This paper reviews these types of drugs and offers recommendations for their use.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease.
Farm Hosp
January 2025
Servicio de Farmacia, Hospital Universitario La Plana, Castellón, España.
Background: Adalimumab biosimilar MSB11022 (Idacio®) has been approved for the same indications as its originator (Humira®), based on findings from clinical trials in plaque psoriasis. Data on its efficacy and safety in inflammatory bowel disease, however, are scarce.
Methods: Retrospective, observational study of 44 patients with inflammatory bowel disease: 30 were treated with originator adalimumab, five were directly started on MSB11022, and nine switched from originator to biosimilar adalimumab.
"Evaluation of Curcuma zedoaria Rosc. in the management of non-alcoholic fatty liver Disease: A Randomized, single blind, controlled trial".
Arab J Gastroenterol
January 2025
PG Dept. of Moalajat, (Medicine) RRIUM, Srinagar, India.
Background And Study Aims: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder, affecting 23% to 32% of the global population. This clinical study aimed to assess the efficacy of Curcuma zedoaria Rosc. compared to vitamin E in managing NAFLD.
View Article and Find Full Text PDFLONG-TERM PROGNOSIS OF NON-CELIAC ENTEROPATHIES AND A SCORE TO IDENTIFY PATIENTS WITH POOR OUTCOMES: A 30-YEAR MULTICENTER LONGITUDINAL STUDY.
Am J Gastroenterol
January 2025
Department of Internal Medicine and Medical Therapeutics, University of Pavia, Italy.
Introduction: Long-term prognosis of non-celiac enteropathies (NCEs) is poorly understood. We aimed to evaluate long-term outcomes and develop a prognostic score for NCEs.
Methods: NCEs patients from an international multicenter cohort (4 Italian centers,1 UK, 1 French,1 Norwegian,1 USA,1 Indian) followed-up over 30 years were enrolled.
Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease.
Front Endocrinol (Lausanne)
January 2025
Department of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou Medical University, Jinzhou, Liaoning, China.
Objective: The impact of lipid-lowering medications on chronic kidney disease (CKD) remains a subject of debate. This Mendelian randomization (MR) study aims to elucidate the potential effects of lipid-lowering drug targets on CKD development.
Methods: We extracted 11 genetic variants encoding targets of lipid-lowering drugs from published genome-wide association study (GWAS) summary statistics, encompassing LDLR, HMGCR, PCSK9, NPC1L1, APOB, ABCG5/ABCG8, LPL, APOC3, ANGPTL3, and PPARA.
Childhood BMI trajectories and sociodemographic factors in an Italian pediatric population.
Sci Rep
January 2025
Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco- Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Childhood obesity is a growing global concern due to its long-term health consequences. Yet, more research relying on multiple time-point BMI measurements is warranted to gain further insight into obesity's temporal trends. We aimed to identify BMI trajectories in children aged 2-10 years and evaluate their association with sociodemographic factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!